DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group
- 9 July 2007
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 43 (11) , 1679-1686
- https://doi.org/10.1016/j.ejca.2007.04.025
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast CancerCancer Research, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell LinesCancer Biology & Therapy, 2003
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343:1350–1354, 2000Neurosurgical Focus, 2001
- Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndromeNature Genetics, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958